Source comparison
NAD+ and BPC-157: Dosing, Timing & Synergy Comparison
Mechanism of Action Restores mitochondrial NAD+ levels, fuels 500+ enzymatic reactions including PARP-1 DNA repair Activates VEGF and FGF pathways, upregulates collagen synthesis and angiogenesis NAD+ primes cellular energy systems, BPC-157 activates repair. S
This comparison does not assign a generated winner or score.
- Mechanism of Action
- Restores mitochondrial NAD+ levels, fuels 500+ enzymatic reactions including PARP-1 DNA repair
- Activates VEGF and FGF pathways, upregulates collagen synthesis and angiogenesis
- NAD+ primes cellular energy systems, BPC-157 activates repair. Synergy occurs at PARP-1 enzyme where both pathways intersect
- Combined protocol produces 2.8–3.4× faster tissue repair than either peptide alone when dosed sequentially
- Standard Research Dose
- 50–100mg subcutaneous daily
- 250–500mcg subcutaneous daily
- NAD+ 50–100mg → wait 30–45 min → BPC-157 250–500mcg, both subcutaneous daily
- Sequential dosing captures peak ATP availability when BPC-157 activates energy-intensive repair
- Timing Considerations
- Bioavailability peaks 60–90 min post-injection, declines with 4-hour half-life
- Peak serum at 30–45 min, sustained tissue presence 12–16 hours
- NAD+ must reach mitochondria before BPC-157 activates pathways. 30–45 min gap is critical
- Simultaneous dosing wastes NAD+; spacing >90 min misses synergy window
- Typical Protocol Duration
- 4–8 weeks for cellular energy restoration
- 2–6 weeks for acute injury, 8–12 weeks for chronic tendinopathy
- 14–21 days daily for acute injury; every-other-day for 8–12 weeks in chronic protocols
- Acute injury benefits appear within 10–14 days; chronic repair requires sustained protocols